Radiation Myelitis After Hypofractionated Spine Stereotactic Body Radiation Therapy
This cohort study characterizes the risk of radiation myelitis after spine stereotactic body radiation therapy to update the current dosimetric constraints.
This cohort study characterizes the risk of radiation myelitis after spine stereotactic body radiation therapy to update the current dosimetric constraints.
An abstract is unavailable.
Dr. Lan Coffman presents updated Phase III MIRASOL trial results comparing overall survival and safety outcomes of mirvetuximab soravtansine (MIRV) versus investigator’s choice chemotherapy in…
Dr. Lan Coffman presents updated Phase III MIRASOL trial results comparing overall survival and safety outcomes of mirvetuximab soravtansine (MIRV) versus investigator’s choice chemotherapy in…
This Medical News article is an interview with Michael Pencina, PhD, Duke Health’s chief data scientist, about the need for health systems to collaborate to…
The Food and Drug Administration granted accelerated approval to encorafenib.
PURPOSETrimodal therapy (TMT) is the standard treatment for patients with nonmetastatic inflammatory breast cancer (IBC). TMT consists of neoadjuvant systemic therapy, modified radical mastectomy (MRM),…
Edited by Associate Editor Michael Hallek and Podcast Editor Laurie H. Sehn, this Review Series highlights the biologic features of, clinical phenotype of,
This Medial News article discusses recent research showing that current COVID-19 vaccines fail to elicit enough of a mucosal immune response to prevent infection.
The FDA granted accelerated approval to encorafenib (Braftovi; Array BioPharma/Pfizer), a BRAF inhibitor, in combination with the anti-EGFR mAb cetuximab (Erbitux; Eli Lilly) and the…
According to data presented at the 66th ASH Annual Meeting, the addition of PXS-5505 to ruxolotinib therapy demonstrated safety and potential efficacy for patients with…